BWA
SUPN icon

Basecamp Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Basecamp Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02K Hold
22
– – ﹤0.01% 1517
2026
Q1 		$1.14K Sell
22
-14
-39% -$713 ﹤0.01% 1531
2025
Q4 		$1.79K Buy
+36
New +$1.75K ﹤0.01% 1378

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Basecamp Wealth Advisors's SUPN Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 22 shares worth $1.02K. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Basecamp Wealth Advisors first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.79K in Q4 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Basecamp Wealth Advisors held 22 shares of Supernus Pharmaceuticals worth $1.02K as of Q2 2026.
  • Basecamp Wealth Advisors left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1517 holding.
  • Basecamp Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Supernus Pharmaceuticals position peaked at $1.79K in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.